Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Clinical Trial

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1742837

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1742837

Agoraphobia

PUBLISHED:
PAGES: 379 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Agoraphobia Market to Reach US$1.4 Billion by 2030

The global market for Agoraphobia estimated at US$1.0 Billion in the year 2024, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Selective Serotonin Reuptake Inhibitor, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$699.2 Million by the end of the analysis period. Growth in the Norepinephrine Reuptake Inhibitor segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$274.8 Million While China is Forecast to Grow at 8.7% CAGR

The Agoraphobia market in the U.S. is estimated at US$274.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$279.1 Million by the year 2030 trailing a CAGR of 8.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Agoraphobia Treatment Market - Key Trends & Drivers Summarized

Why Is Agoraphobia Receiving Heightened Clinical Attention Amid Rising Mental Health Awareness and Accessibility Challenges?

Agoraphobia, characterized by intense fear or anxiety in situations where escape may be difficult or help unavailable-such as crowded places, public transportation, or open spaces-can significantly impair a person's quality of life and functional independence. Often linked with panic disorder, agoraphobia can manifest as avoidance behavior, social withdrawal, and long-term disability if left untreated. As mental health becomes a core component of global public health discourse, agoraphobia is receiving renewed focus within diagnostic, therapeutic, and public policy frameworks.

Increased digital screening tools, rising societal awareness, and shifting cultural perceptions around anxiety disorders are contributing to earlier identification and intervention. Telepsychiatry and digital cognitive behavioral therapy (CBT) platforms are also expanding access to care for individuals who, due to their condition, may struggle with in-person treatment formats.

How Are Pharmacological and Psychotherapeutic Advances Enhancing Outcomes for Agoraphobia Patients?

First-line treatments include cognitive behavioral therapy, exposure-based interventions, and selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). These therapies aim to recalibrate fear responses, reduce avoidance behaviors, and improve functional coping mechanisms. Benzodiazepines may be used selectively for acute anxiety relief but are increasingly limited due to dependence risk and adverse effect profiles.

Technology-enabled therapies, such as virtual reality (VR)-assisted exposure and app-based CBT modules, are making significant strides in delivering controlled, scalable treatment environments. Personalized therapy plans, supported by real-time monitoring and digital feedback loops, are improving treatment adherence and customization. Pharmaceutical innovation is also exploring next-generation anxiolytics and neuromodulators with faster onset and improved tolerability profiles.

Which Demographics and Healthcare Ecosystems Are Driving Demand for Agoraphobia Management?

Agoraphobia commonly presents in late adolescence to early adulthood, with higher prevalence among women and individuals with a history of panic attacks or trauma. Urbanization, pandemic-induced isolation, and digital overstimulation are contributing to rising incidence rates in both developed and emerging economies. Healthcare systems are increasingly recognizing agoraphobia as a public health concern linked to broader productivity losses, comorbid depression, and social exclusion.

North America and Europe lead in diagnosis and treatment availability, supported by established mental health infrastructure, reimbursement frameworks, and awareness campaigns. Asia-Pacific is experiencing rising demand, particularly in metropolitan centers, as mental health literacy grows and telemedicine platforms gain traction. In low-resource settings, NGO-led interventions and mobile mental health services are playing a critical role in closing care gaps.

How Are Policy Shifts, Stigma Reduction, and Digital Therapeutics Reshaping Market Dynamics?

Global mental health policy is shifting from crisis intervention toward prevention and early treatment, positioning agoraphobia within broader anxiety and mood disorder strategies. Anti-stigma campaigns, workplace mental health programs, and school-based screening initiatives are normalizing help-seeking behavior and enabling early clinical engagement.

Digital therapeutics are emerging as scalable, evidence-backed tools for delivering therapy beyond traditional clinical settings. Regulatory acceptance of digital health apps and remote monitoring tools is opening new reimbursement pathways and expanding market access. Meanwhile, insurers and employers are increasingly supporting mental health benefits, including agoraphobia-specific interventions, as part of holistic wellness models.

What Are the Factors Driving Growth in the Agoraphobia Treatment Market?

The agoraphobia treatment market is growing due to increased mental health prioritization, expanding access to psychotherapeutic and pharmacological options, and the rapid integration of digital care delivery. Key growth drivers include improved diagnosis rates, the rise of tech-enabled therapy models, supportive policy environments, and deeper understanding of anxiety disorder neurobiology. As demand for non-stigmatizing, accessible, and personalized mental healthcare rises, agoraphobia is gaining visibility as a treatable, high-impact condition.

Looking ahead, the market’s evolution will depend on how effectively healthcare systems bridge clinical innovation with equitable access and long-term behavioral outcomes. As digital ecosystems and therapeutic platforms converge, could the future of agoraphobia care unlock scalable models for addressing chronic anxiety across global populations?

SCOPE OF STUDY:

The report analyzes the Agoraphobia market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Treatment (Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication, Other Drug Treatments); Therapy (Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy, Other Therapies); End-Use (Hospitals, Clinics, Academic, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

  • A Mission for Michael (AMFM)
  • Apotex Inc.
  • AstraZeneca
  • Blair Wellness Group
  • Boston Neurobehavioral Associates
  • Bristol-Myers Squibb
  • Center for the Treatment and Study of Anxiety
  • Eli Lilly and Company
  • Essex Industries
  • Fennica Oy
  • GlaxoSmithKline plc
  • Honeywell Aerospace
  • Johnson & Johnson
  • Lifestance Health
  • Meggitt PLC
  • Mindable GmbH
  • Mylan Pharmaceuticals
  • NYCO
  • OCD & Anxiety Specialists of Dallas
  • Pfizer Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP34560

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Agoraphobia - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Mental Health Awareness Throws the Spotlight on Agoraphobia Diagnosis and Treatment Demand
    • Increased Reporting and Early Screening Drive Higher Identification Rates Among Agoraphobic Patients
    • Expansion of Digital Mental Health Services Spurs Access to Therapy for Housebound Individuals
    • Advances in Cognitive Behavioral Therapy (CBT) Platforms Strengthen the Business Case for Non-Pharmacologic Interventions
    • Growth in Use of Mobile Mental Health Apps Bodes Well for Self-Guided Agoraphobia Management Tools
    • Pharmaceutical Development of Targeted Anti-Anxiety Medications Supports Symptom Control
    • Surge in Virtual Reality Exposure Therapy Expands Treatment Modalities for Severe Cases
    • Increased Access to Telehealth Enables Timely Interventions for Rural and Homebound Populations
    • Integration of AI and Chatbots in Therapy Settings Facilitates Low-Barrier Entry to Support Services
    • Rising Demand for Personalized Psychiatry Fuels R&D in Genetics-Based Treatment Optimization
    • Expansion of Mental Health Insurance Coverage Improves Affordability of Long-Term Care Plans
    • Public Health Campaigns and Destigmatization Efforts Strengthen Awareness and Encourage Treatment Uptake
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Agoraphobia Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Agoraphobia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Agoraphobia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Agoraphobia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Selective Serotonin Reuptake Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Selective Serotonin Reuptake Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Selective Serotonin Reuptake Inhibitor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Norepinephrine Reuptake Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Norepinephrine Reuptake Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Norepinephrine Reuptake Inhibitor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Anti-Anxiety Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Anti-Anxiety Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Anti-Anxiety Medication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Drug Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Academic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Academic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Academic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Psychotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Psychotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Psychotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Cognitive Behavioral Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Cognitive Behavioral Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Cognitive Behavioral Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Exposure Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Exposure Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Exposure Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Agoraphobia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • JAPAN
    • Agoraphobia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • CHINA
    • Agoraphobia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • EUROPE
    • Agoraphobia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Agoraphobia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Agoraphobia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Agoraphobia by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • FRANCE
    • Agoraphobia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • GERMANY
    • Agoraphobia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Agoraphobia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Agoraphobia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Agoraphobia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Agoraphobia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Agoraphobia by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Agoraphobia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • INDIA
    • Agoraphobia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Agoraphobia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Agoraphobia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Agoraphobia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Agoraphobia by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Agoraphobia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Agoraphobia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Agoraphobia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Agoraphobia by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030
  • AFRICA
    • Agoraphobia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Agoraphobia by Drug Treatment - Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Agoraphobia by Drug Treatment - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitor, Norepinephrine Reuptake Inhibitor, Anti-Anxiety Medication and Other Drug Treatments for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Agoraphobia by End-Use - Clinics, Academic, Other End-Uses and Hospitals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Agoraphobia by End-Use - Percentage Breakdown of Value Sales for Clinics, Academic, Other End-Uses and Hospitals for the Years 2015, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Agoraphobia by Therapy - Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Agoraphobia by Therapy - Percentage Breakdown of Value Sales for Psychotherapy, Cognitive Behavioral Therapy, Exposure Therapy and Other Therapies for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!